Share Price and Basic Stock Data
Last Updated: December 5, 2025, 4:48 am
| PEG Ratio | -5.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Adeshwar Meditex Ltd operates within the medical equipment and accessories sector, a field that has seen considerable innovation and growth, especially post-pandemic. The company reported sales of ₹82.36 Cr for the fiscal year ending March 2023, up from ₹64.76 Cr in the previous year, indicating a robust recovery and a strong demand for its products. However, revenue trends have shown some volatility; for instance, sales dipped slightly to ₹79.85 Cr in FY 2024 before rebounding to ₹83.71 Cr in FY 2025. This fluctuation may raise concerns about the sustainability of growth, but the recent uptick suggests that the company is regaining its footing. Notably, the operating profit margin (OPM) has hovered around 5.82% in the latest quarter, reflecting operational challenges amidst rising costs. The cash conversion cycle at 175.13 days indicates that the company may be experiencing delays in converting its investments into cash, which can impact liquidity in the short term. Overall, while Adeshwar Meditex appears well-positioned to capitalize on industry trends, the revenue variability warrants close monitoring.
Profitability and Efficiency Metrics
The profitability metrics for Adeshwar Meditex provide a mixed picture. The net profit for FY 2025 stood at ₹2.07 Cr, consistent with the previous year, which reflects a stabilizing trend. However, the return on equity (ROE) at 5.51% and return on capital employed (ROCE) at 8.27% indicate that the company is not maximizing shareholder value as effectively as it could. A closer look at operating profit reveals fluctuations, with the OPM falling to 4.78% in the latest quarter, suggesting that rising operational costs might be squeezing margins. Additionally, the interest coverage ratio (ICR) of 3.47x seems comfortable, indicating that the company can meet its interest obligations without undue stress. However, the cash conversion cycle of 175.13 days raises concerns about operational efficiency, suggesting that the company may need to enhance inventory management and receivables collection to improve cash flow. While profitability metrics show potential, they also highlight areas needing attention for better efficiency and margin expansion.
Balance Sheet Strength and Financial Ratios
Adeshwar Meditex’s balance sheet reflects a cautious approach to leverage, with total borrowings at ₹12.45 Cr against reserves of ₹22.53 Cr. This translates to a debt-to-equity ratio of approximately 0.33, which is relatively low, indicating that the company is not overly reliant on debt financing. The company’s current ratio stands at a healthy 2.03, suggesting a robust liquidity position to meet short-term liabilities. However, the price-to-book value (P/BV) ratio of 0.65x indicates that the stock may be undervalued relative to its net assets, which could attract value investors. The inventory turnover ratio of 3.20x signals that the company is efficiently managing its stock levels, although the cash conversion cycle could still be optimized. Overall, while the balance sheet appears sound, the company must remain vigilant regarding its working capital management to ensure financial flexibility in a dynamic market.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Adeshwar Meditex reveals a significant level of commitment from its promoters, who hold 57.55% of the company. This high level of promoter ownership can instill confidence among retail investors, as it often suggests alignment of interests between management and shareholders. The public shareholding, however, has decreased to 42.44%, down from a higher 57.35% in earlier periods, which may raise questions about market sentiment and investor interest. The number of shareholders has remained relatively stable at around 187, indicating a consistent base of retail investors. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) could be a concern, as institutional backing often brings stability and credibility. While the promoter stake is a strong point, the declining public interest and lack of institutional investment may suggest underlying apprehensions about the company’s growth trajectory or market performance.
Outlook, Risks, and Final Insight
Looking ahead, Adeshwar Meditex faces both opportunities and challenges. The growing demand for medical equipment positions the company favorably, yet it must navigate operational inefficiencies and market volatility. The company’s relatively low ROE and high cash conversion cycle highlight areas for improvement; addressing these could lead to enhanced profitability and investor confidence. Risks include potential disruptions in supply chains, which could affect production and inventory levels, alongside competitive pressures in the medical equipment sector. Additionally, the reliance on domestic sales, without substantial institutional backing, might expose the company to market fluctuations. Investors should consider these factors carefully. While the fundamentals reflect some strengths, the path forward will require strategic focus on operational efficiency and market engagement to realize its growth potential. Overall, a cautious yet optimistic approach may be warranted as the company works to solidify its position in the industry and enhance shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Adeshwar Meditex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 77.7 Cr. | 62.0 | 129/46.0 | 17.6 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 36.6 Cr. | 100 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 23.8 Cr. | 16.5 | 26.5/15.0 | 11.5 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 18,873 Cr. | 1,862 | 3,032/1,821 | 52.1 | 288 | 0.18 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 73.2 Cr. | 40.2 | 86.9/40.2 | 21.9 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 18,873.00 Cr | 416.14 | 25.78 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.53 | 29.45 | 30.21 | 34.54 | 46.06 | 36.30 | 46.26 | 33.59 | 40.90 | 37.45 |
| Expenses | 34.90 | 26.47 | 28.12 | 33.25 | 43.33 | 33.84 | 44.05 | 30.61 | 38.90 | 35.27 |
| Operating Profit | 1.63 | 2.98 | 2.09 | 1.29 | 2.73 | 2.46 | 2.21 | 2.98 | 2.00 | 2.18 |
| OPM % | 4.46% | 10.12% | 6.92% | 3.73% | 5.93% | 6.78% | 4.78% | 8.87% | 4.89% | 5.82% |
| Other Income | 0.09 | 0.17 | 0.02 | 0.21 | 0.08 | 0.22 | 0.08 | 0.05 | 0.21 | 0.17 |
| Interest | 1.08 | 1.11 | 1.02 | 1.01 | 1.04 | 1.01 | 1.03 | 0.90 | 0.71 | 0.31 |
| Depreciation | 0.17 | 0.17 | 0.17 | 0.22 | 0.26 | 0.27 | 0.29 | 0.31 | 0.25 | 0.21 |
| Profit before tax | 0.47 | 1.87 | 0.92 | 0.27 | 1.51 | 1.40 | 0.97 | 1.82 | 1.25 | 1.83 |
| Tax % | 29.79% | 27.27% | 26.09% | 59.26% | 27.81% | 29.29% | 25.77% | 29.12% | 28.00% | 27.32% |
| Net Profit | 0.33 | 1.36 | 0.68 | 0.11 | 1.09 | 0.99 | 0.73 | 1.28 | 0.90 | 1.34 |
| EPS in Rs | 0.63 | 1.29 | 0.47 | 0.08 | 0.76 | 0.69 | 0.51 | 0.89 | 0.62 | 0.93 |
Last Updated: May 31, 2025, 7:10 am
Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 37.45 Cr.. The value appears to be declining and may need further review. It has decreased from 40.90 Cr. (Sep 2024) to 37.45 Cr., marking a decrease of 3.45 Cr..
- For Expenses, as of Mar 2025, the value is 35.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.90 Cr. (Sep 2024) to 35.27 Cr., marking a decrease of 3.63 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.18 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 2.18 Cr., marking an increase of 0.18 Cr..
- For OPM %, as of Mar 2025, the value is 5.82%. The value appears strong and on an upward trend. It has increased from 4.89% (Sep 2024) to 5.82%, marking an increase of 0.93%.
- For Other Income, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Mar 2025, the value is 0.31 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.71 Cr. (Sep 2024) to 0.31 Cr., marking a decrease of 0.40 Cr..
- For Depreciation, as of Mar 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.25 Cr. (Sep 2024) to 0.21 Cr., marking a decrease of 0.04 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 1.25 Cr. (Sep 2024) to 1.83 Cr., marking an increase of 0.58 Cr..
- For Tax %, as of Mar 2025, the value is 27.32%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to 27.32%, marking a decrease of 0.68%.
- For Net Profit, as of Mar 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.90 Cr. (Sep 2024) to 1.34 Cr., marking an increase of 0.44 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.93. The value appears strong and on an upward trend. It has increased from 0.62 (Sep 2024) to 0.93, marking an increase of 0.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:03 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 58.60 | 52.92 | 56.12 | 65.97 | 64.76 | 82.36 | 79.85 | 83.71 |
| Expenses | 52.96 | 47.44 | 50.64 | 61.22 | 61.39 | 77.14 | 74.66 | 79.29 |
| Operating Profit | 5.64 | 5.48 | 5.48 | 4.75 | 3.37 | 5.22 | 5.19 | 4.42 |
| OPM % | 9.62% | 10.36% | 9.76% | 7.20% | 5.20% | 6.34% | 6.50% | 5.28% |
| Other Income | 0.10 | 0.25 | 0.28 | 0.13 | 0.23 | 0.31 | 0.13 | 0.26 |
| Interest | 1.78 | 2.23 | 2.52 | 2.19 | 2.03 | 2.09 | 1.93 | 1.39 |
| Depreciation | 0.36 | 0.35 | 0.34 | 0.35 | 0.38 | 0.53 | 0.60 | 0.50 |
| Profit before tax | 3.60 | 3.15 | 2.90 | 2.34 | 1.19 | 2.91 | 2.79 | 2.79 |
| Tax % | 29.72% | 28.25% | 27.24% | 28.63% | 33.61% | 28.52% | 27.96% | 26.16% |
| Net Profit | 2.54 | 2.26 | 2.12 | 1.68 | 0.79 | 2.07 | 2.01 | 2.07 |
| EPS in Rs | 5.10 | 4.54 | 4.03 | 1.60 | 0.55 | 1.43 | 1.39 | 1.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -11.02% | -6.19% | -20.75% | -52.98% | 162.03% | -2.90% | 2.99% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.83% | -14.56% | -32.22% | 215.00% | -164.92% | 5.88% |
Adeshwar Meditex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 36% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:06 pm
Balance Sheet
Last Updated: September 10, 2025, 2:54 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.98 | 4.98 | 5.27 | 10.53 | 14.43 | 14.43 | 14.43 | 14.43 |
| Reserves | 8.55 | 10.81 | 13.64 | 10.05 | 16.52 | 18.48 | 20.48 | 22.53 |
| Borrowings | 11.58 | 19.92 | 21.32 | 22.45 | 18.99 | 16.43 | 13.89 | 12.45 |
| Other Liabilities | 7.33 | 5.79 | 14.57 | 19.27 | 22.63 | 17.67 | 15.23 | 22.79 |
| Total Liabilities | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 |
| Fixed Assets | 2.36 | 2.44 | 2.28 | 2.24 | 3.03 | 3.70 | 3.53 | 2.95 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.04 | 0.08 | 0.08 | 0.10 | 0.10 | 0.10 | 0.00 |
| Other Assets | 30.06 | 39.02 | 52.44 | 59.98 | 69.44 | 63.21 | 60.40 | 69.25 |
| Total Assets | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 |
Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.43 Cr..
- For Reserves, as of Mar 2025, the value is 22.53 Cr.. The value appears strong and on an upward trend. It has increased from 20.48 Cr. (Mar 2024) to 22.53 Cr., marking an increase of 2.05 Cr..
- For Borrowings, as of Mar 2025, the value is 12.45 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.89 Cr. (Mar 2024) to 12.45 Cr., marking a decrease of 1.44 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.79 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.23 Cr. (Mar 2024) to 22.79 Cr., marking an increase of 7.56 Cr..
- For Total Liabilities, as of Mar 2025, the value is 72.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.95 Cr.. The value appears to be declining and may need further review. It has decreased from 3.53 Cr. (Mar 2024) to 2.95 Cr., marking a decrease of 0.58 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For Other Assets, as of Mar 2025, the value is 69.25 Cr.. The value appears strong and on an upward trend. It has increased from 60.40 Cr. (Mar 2024) to 69.25 Cr., marking an increase of 8.85 Cr..
- For Total Assets, as of Mar 2025, the value is 72.20 Cr.. The value appears strong and on an upward trend. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
Notably, the Reserves (22.53 Cr.) exceed the Borrowings (12.45 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.94 | -14.44 | -15.84 | -17.70 | -15.62 | -11.21 | -8.70 | -8.03 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 108.69 | 134.63 | 181.26 | 150.82 | 183.06 | 123.78 | 115.51 | 152.52 |
| Inventory Days | 64.44 | 112.51 | 119.36 | 174.35 | 168.24 | 127.72 | 138.71 | 126.64 |
| Days Payable | 43.11 | 38.76 | 104.70 | 119.86 | 138.51 | 88.18 | 75.97 | 104.03 |
| Cash Conversion Cycle | 130.02 | 208.39 | 195.93 | 205.31 | 212.79 | 163.33 | 178.25 | 175.13 |
| Working Capital Days | 129.43 | 108.29 | 124.03 | 111.49 | 147.05 | 116.60 | 129.04 | 135.78 |
| ROCE % | 17.69% | 14.27% | 11.22% | 6.93% | 10.07% | 9.62% | 8.27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.55 | 1.59 |
| Diluted EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.59 | 1.59 |
| Cash EPS (Rs.) | 1.78 | 1.81 | 1.80 | 0.81 | 1.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Revenue From Operations / Share (Rs.) | 58.01 | 55.33 | 57.07 | 44.87 | 62.64 |
| PBDIT / Share (Rs.) | 3.21 | 3.68 | 3.80 | 2.49 | 4.76 |
| PBIT / Share (Rs.) | 2.86 | 3.26 | 3.43 | 2.23 | 4.43 |
| PBT / Share (Rs.) | 1.94 | 1.93 | 2.01 | 0.82 | 2.36 |
| Net Profit / Share (Rs.) | 1.43 | 1.39 | 1.44 | 0.54 | 1.59 |
| PBDIT Margin (%) | 5.52 | 6.64 | 6.66 | 5.55 | 7.60 |
| PBIT Margin (%) | 4.93 | 5.89 | 6.01 | 4.96 | 7.08 |
| PBT Margin (%) | 3.33 | 3.48 | 3.52 | 1.83 | 3.76 |
| Net Profit Margin (%) | 2.46 | 2.51 | 2.51 | 1.22 | 2.54 |
| Return on Networth / Equity (%) | 5.58 | 5.75 | 6.30 | 2.56 | 8.14 |
| Return on Capital Employeed (%) | 10.49 | 12.96 | 13.89 | 9.06 | 17.68 |
| Return On Assets (%) | 2.86 | 3.13 | 3.09 | 1.09 | 2.69 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.13 | 0.25 |
| Total Debt / Equity (X) | 0.33 | 0.39 | 0.44 | 0.55 | 0.98 |
| Asset Turnover Ratio (%) | 1.23 | 1.22 | 1.18 | 0.96 | 1.13 |
| Current Ratio (X) | 2.03 | 2.06 | 1.90 | 1.76 | 1.59 |
| Quick Ratio (X) | 1.25 | 1.10 | 1.12 | 1.07 | 0.86 |
| Inventory Turnover Ratio (X) | 3.20 | 2.86 | 2.81 | 2.21 | 3.22 |
| Interest Coverage Ratio (X) | 3.47 | 2.76 | 2.68 | 1.78 | 2.29 |
| Interest Coverage Ratio (Post Tax) (X) | 2.55 | 2.04 | 2.01 | 1.39 | 1.83 |
| Enterprise Value (Cr.) | 33.89 | 60.21 | 36.79 | 54.94 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.75 | 0.44 | 0.84 | 0.00 |
| EV / EBITDA (X) | 7.33 | 11.34 | 6.71 | 15.26 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| Price / BV (X) | 0.65 | 1.36 | 0.73 | 1.28 | 0.00 |
| Price / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| EarningsYield | 0.08 | 0.04 | 0.08 | 0.02 | 0.00 |
After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.78. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.78, marking a decrease of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
- For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.46, marking a decrease of 0.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.58, marking a decrease of 0.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
- For Return On Assets (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.86, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 4. It has increased from 2.86 (Mar 24) to 3.20, marking an increase of 0.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.55. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.55, marking an increase of 0.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.08, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adeshwar Meditex Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.49% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.58% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 11.5 (Industry average Stock P/E: 25.78)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.33
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
Fundamental Analysis of Adeshwar Meditex Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 68, 6th Floor, Plot 209, Atlanta Building, Mumbai Maharashtra 400021 | adeshwarmedi@gmail.com http://www.adeshwarmeditex.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Ashalata Baburao Raut | Whole Time Director |
| Mr. Krishnojirao Nagaraja Rao | Whole Time Director |
| Ms. Sucheta Sidharth Talati | Non Executive Director |
| Mr. Shailesh Vinayak Rajpure | Director |
| Mr. Benegal Parameshwara Udpa | Ind. Non-Executive Director |
| Mr. Arun Koli | Ind. Non-Executive Director |
Adeshwar Meditex Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹29.45 |
| Previous Day | ₹29.45 |
FAQ
What is the intrinsic value of Adeshwar Meditex Ltd?
Adeshwar Meditex Ltd's intrinsic value (as of 07 December 2025) is 13.50 which is 18.18% lower the current market price of 16.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 23.8 Cr. market cap, FY2025-2026 high/low of 26.5/15.0, reserves of ₹22.53 Cr, and liabilities of 72.20 Cr.
What is the Market Cap of Adeshwar Meditex Ltd?
The Market Cap of Adeshwar Meditex Ltd is 23.8 Cr..
What is the current Stock Price of Adeshwar Meditex Ltd as on 07 December 2025?
The current stock price of Adeshwar Meditex Ltd as on 07 December 2025 is 16.5.
What is the High / Low of Adeshwar Meditex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Adeshwar Meditex Ltd stocks is 26.5/15.0.
What is the Stock P/E of Adeshwar Meditex Ltd?
The Stock P/E of Adeshwar Meditex Ltd is 11.5.
What is the Book Value of Adeshwar Meditex Ltd?
The Book Value of Adeshwar Meditex Ltd is 26.1.
What is the Dividend Yield of Adeshwar Meditex Ltd?
The Dividend Yield of Adeshwar Meditex Ltd is 0.00 %.
What is the ROCE of Adeshwar Meditex Ltd?
The ROCE of Adeshwar Meditex Ltd is 8.27 %.
What is the ROE of Adeshwar Meditex Ltd?
The ROE of Adeshwar Meditex Ltd is 5.51 %.
What is the Face Value of Adeshwar Meditex Ltd?
The Face Value of Adeshwar Meditex Ltd is 10.0.